AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 9 - (NewsRx.com & NewsRx.net) -- The successful treatment of a pancreatic cancer patient who received multiple doses of a vaccine consisting of dendritic cells pulsed with allogeneic tumor lysate may provide insights into new therapeutic strategies.
According to a study from Austria, "The objective of this study was to assess the toxicity and immunological response induced by autologous dendritic cells (DCs) pulsed with allogeneic tumor lysate in a pancreatic cancer patient. The lack of available tumor peptide in pancreatic cancer strongly supports the idea to use allogeneic tumor cells as a source of antigens."
"The patient suffering from a stage IV pancreatic cancer received 1-2x10[superscript]7 autologous monocyte-derived DCs in 3-week intervals injected into a groin lymph node," reported A. Stift and collaborators at the University of Vienna. "Monocytes from peripheral blood were isolated by magnetic bead selection. For the first ten vaccinations DCs were loaded with autologous tumor cell lysate obtained during surgical exploration. After consumption of the autologous lysate, equal numbers of DCs were pulsed with lysate of the tumor cell line AsPc-1 and BxPc-3 for a further five vaccinations. Peripheral mononuclear cells (PMNCs) were harvested after the seventh and compared with PMNCs obtained after the fourteenth vaccination for immunological response. Delayed type hypersensitivity reactivity to DCs pulsed with autologous and allogeneic tumor lysate was also assessed."
"The patient received a total of fifteen vaccinations," stated the investigators. "There was no toxicity or evidence of autoimmunity ...